BridgeBio Pharma News

BridgeBio Pharma Is Maintained at Outperform by Evercore ISI Group

Dow JonesDec 24 02:05 · Ratings

Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $50

Futu NewsDec 23 22:32 · Ratings

Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46

Futu NewsDec 19 07:32 · Ratings

Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives

TipRanksDec 18 13:25 · Ratings

H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49

Futu NewsDec 16 20:31 · Ratings

BridgeBio Pharma Analyst Ratings

BenzingaDec 16 20:20 · Ratings

BridgeBio Pharma's Growth Prospects Bolstered by Acoramidis Approval and Promising Pipeline

TipRanksDec 16 19:36

Bridgebio Pharma Says Committee For Medicinal Products For Human Use (CHMP) Recommends Marketing Authorization In European Union For Acoramidis For The Treatment Of Wild-type Or Variant Transthyretin Amyloidosis In Adult Patients With Cardiomyopathy...

BenzingaDec 13 20:21

Express News | EMA's Chmp: Adopted Positive Opinion for Beyonttra (Acoramidis)

BreakingsDec 13 19:35

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)

TipRanksDec 9 20:10 · Ratings

Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform

BenzingaDec 3 21:05

Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating

Futu NewsNov 27 14:31 · Ratings

Trending Stocks Today | Ambarella Surges 24.58% Post-Market

November 26th - US stocks trending post-market.Gainers: $Ambarella(AMBA.US)$ shoots up 24.58% to $85.23 with a turnover of $17.9 million. $Nutanix(NTNX.US)$ up 7.69% to $77.92 with a turnover of $20.1

Futu NewsNov 27 05:20

BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby (Acoramidis)

PR NewswireNov 27 00:31

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

Zacks Nov 26 23:05

A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $45 to $55

Futu NewsNov 26 21:00 · Ratings

Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $48

BenzingaNov 26 07:22 · Ratings

12 Health Care Stocks Moving In Monday's Pre-Market Session

BenzingaNov 26 05:05

BridgeBio Pharma Up Over 16%, on Pace for Largest Percent Increase Since July 2023 -- Data Talk

Dow JonesNov 26 03:41

Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY (Acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis

PR NewswireNov 26 03:30